Open Access iconOpen Access

ARTICLE

crossmark

Pomalidomide improves the function of CD133- or HER2-specific CAR T cells

by Zhixiong Wang1,2, Na Risu2, Jiayu Fu2, Hui Liu3, Guomin Zhou3, Qian Liu3, Yan Zou4, Jiaxing Tang4, Long Li4, Xuekai Zhu4,*

1 Ma’anshan University, Ma’anshan, 243100, China
2 Division of Health Science, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan
3 School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China
4 Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, 201210, China

* Address correspondence to: Xuekai Zhu, email

BIOCELL 2021, 45(1), 157-165. https://doi.org/10.32604/biocell.2021.010261

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is mostly limited to hematological malignancies and has a poor effect on solid tumors. CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs such as pomalidomide, so the use of pomalidomide may improve the effect of CAR T cells on solid tumors. In this study, CD133- or HER2-specific CAR T cells were chosen to investigate whether pomalidomide can regulate the function of CAR T cells in vitro. We found that pomalidomide can significantly enhance the ability of CD133-CAR T cells and HER2-CAR T cells to kill tumor cells and increase the cytokine secretion of CD133-CAR T cells and HER2-CAR T cells. Also, pomalidomide was shown to induce down-regulation of protein levels of IL-2 transcriptional repressors Aiolos and Ikaros in CAR T cells. This study suggests that the combination of pomalidomide and CAR T cells may be a new strategy for the treatment of solid tumors.

Keywords


Cite This Article

APA Style
WANG, Z., RISU, N., FU, J., LIU, H., ZHOU, G. et al. (2021). Pomalidomide improves the function of CD133- or her2-specific CAR T cells. BIOCELL, 45(1), 157-165. https://doi.org/10.32604/biocell.2021.010261
Vancouver Style
WANG Z, RISU N, FU J, LIU H, ZHOU G, LIU Q, et al. Pomalidomide improves the function of CD133- or her2-specific CAR T cells. BIOCELL . 2021;45(1):157-165 https://doi.org/10.32604/biocell.2021.010261
IEEE Style
Z. WANG et al., “Pomalidomide improves the function of CD133- or HER2-specific CAR T cells,” BIOCELL , vol. 45, no. 1, pp. 157-165, 2021. https://doi.org/10.32604/biocell.2021.010261



cc Copyright © 2021 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 2579

    View

  • 1406

    Download

  • 0

    Like

Related articles

Share Link